ABSTRACT
<p><b>OBJECTIVE</b>Quantitative study of the effect of anti-human VEGF mAb E11 to VEGF level in serum of nude mice transplanted buccal carcinoma.</p><p><b>METHODS</b>E11 was administered into BALB/c nu/nu mice which were transplanted human buccal carcinoma. The saline was administrated as negative control. Mice were killed at 18 days. The VEGF level in serum of mice was determined by improved indirect ELISA.</p><p><b>RESULTS</b>Compared with the VEGF level in serum of mice in saline group, it was dramatically decreased in E11 group. The VEGF level in serum of mice treated E11 by subcutaneous was lowest and only reached (1.17 +/- 0.13) microg/L.</p><p><b>CONCLUSION</b>It demonstrated that the anti-human VEGF mAb could reduce the VEGF level in serum by binding VEGF, and block its biological activity. It indicates that VEGF in serum of malignant tumor patient is a new tumor marker.</p>
Subject(s)
Animals , Humans , Antibodies, Monoclonal , Pharmacology , Biomarkers, Tumor , Blood , Carcinoma , Blood , Mice, Inbred BALB C , Mice, Nude , Mouth Mucosa , Pathology , Neoplasm Transplantation , Neoplasms , Blood , Vascular Endothelial Growth Factor A , BloodABSTRACT
<p><b>OBJECTIVE</b>The aim of this study was to investigate the mechanism(MDR) of multidrug resistance(MDR) of mucoepidermoid carcinoma in salivary gland.</p><p><b>METHODS</b>40 cases of mucoepidermoid carcinoma in salivary gland were examined the MDR gene product P-glycoprotein using a monoclonal antibody JSB-1. And 10 of them were also investigated by detecting the expression of GST-pi. All the cases had not been accepted any therapy before the samples were collected.</p><p><b>RESULTS</b>1. Positive expression of JSB-1 was observed in 27 of the 40 specimens. The positive expression was related not only with clinical stage, but also with differentiation degree. 2. The GST-pi positive expression was found in 9 of 10 cases. There was no significant different between the positive expression of JSB-1 and GST-pi.</p><p><b>CONCLUSION</b>JSB-1 and GST-pi play an important role in MDR of mucoepidermoid carcinoma.</p>
Subject(s)
Adolescent , Adult , Aged , Child , Female , Humans , Male , Middle Aged , ATP Binding Cassette Transporter, Subfamily B, Member 1 , Antibodies, Monoclonal , Carcinoma, Mucoepidermoid , Allergy and Immunology , Drug Resistance, Multiple , Genetics , Drug Resistance, Neoplasm , Genetics , Genes, MDR , Glutathione S-Transferase pi , Glutathione Transferase , Isoenzymes , Salivary Gland Neoplasms , Allergy and Immunology , Salivary Glands , Allergy and ImmunologyABSTRACT
<p><b>OBJECTIVE</b>To study the treatment outcome of rhabdomysarcoma(RMS).</p><p><b>METHODS</b>74 cases of RMS with definite pathologic diagnosis treated in our department during the past 20 years were investigated. The relationship between the therapy and prognosis was analyzed.</p><p><b>RESULTS</b>52 cases among the 74 patients received different surgical treatment and post-operative radiotherapy. 22 cases received radiotherapy or chemoradiotherapy without surgical treatment. The survival rates demonstrated great differences depending on the different clinical stages and therapy.</p><p><b>CONCLUSION</b>The combined therapy including radiotherapy after surgical treatment may increase 5-year survival rate.</p>